Franjo Hanzl
Vice President Commercial Development Europe
Expertise:
As a leader of the commercial team in Europe, Franjo helps clients solve complex industry challenges while supporting streamlined commercialisation strategies that get innovative therapies to patients across borders. He joined EVERSANA with more than 25 years of experience in the life sciences industry and has led global launches across six continents in his career. Franjo has extensive expertise in marketing, business development, and pharmaceutical partnership and alliance management through his work with branded and generic pharma in Europe, which also provides him with a deep knowledge of the pricing landscape.
Franjo holds a master’s degree in pharmacy from the University of Zagreb in Croatia.
Articles by Franjo Hanzl
Why Launching in Europe Is Unlike Launching Anywhere Else
Today, there are more than half a billion people in the European Union (EU) and United Kingdom (U.K.). Passing over this part of the globe puts patients and manufacturers at risk for negative outcomes. Launching a new therapy in the EU and U.K. has traditionally involved complex navigation of service providers, price sequencing and the rich diversity of patient and healthcare provider populations. As a result, bringing a pharmaceutical or biotech product to Europe has been, and continues to be, intimidating for most manufacturers. Many manufacturers still believe that the traditional launch model – signing a handful of disjointed partnerships – is the only way to launch a new product […]
Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers
COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma with recent changes, including the Pharmaceutical Strategy for Europe. But one element of the European pharma industry that remains constant is product distribution through parallel trade. In 2012, parallel trade activity rose by up to 25% in some countries; but distributing a product across territories with diverse regulations, cultures and languages is complex. Now, there is an even more efficient way for manufacturers to distribute treatments in Europe. The answer is one end-to-end commercialization […]